A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Garcia Casado, Zaida ^a   Guerrero Zotano, Angel ^a   Llombart Cussac, Antonio ^b   Calatrava, Ana ^a   Fernandez Serra, Antonio ^a   Ruiz Simon, Amparo ^a   Gavila, Joaquin ^a   Climent, Miguel A ^a   Almenar, Sergio ^a   Cervera Deval, Jose ^a   Campos, Josefina ^a   Albaladejo, Carlos V ^a   Llombart Bosch, Antonio ^c   Guillem, Vicente ^a   Lopez Guerrero, Jose A ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b Hospital Arnau de Villanova   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; HORMONE RECEPTOR; LETROZOLE; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

3' UNTRANSLATED REGION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DNA POLYMORPHISM; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENE LOCATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST TUMOR; DISEASE COURSE; GENETIC POLYMORPHISM; GENETICS; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

3' UNTRANSLATED REGIONS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; POLYMORPHISM, GENETIC; POSTMENOPAUSE; TREATMENT OUTCOME; TRIAZOLES;

EID: 77649178123     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-36     Document Type: Article

References (43)

1. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994, 15(3):342-355.
2. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005, 57(3):359-383. 10.1124/pr.57.3.6, 16109840.
3. Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int J Cancer 2006, 118(8):1915-1921. 10.1002/ijc.21562, 16287071.
4. O'Neill JS, Elton RA, Miller WR. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J (Clin Res Ed) 1988, 296(6624):741-743. 10.1136/bmj.296.6624.741, 2545365, 3126957.
5. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 1996, 81(11):3843-3849. 10.1210/jc.81.11.3843, 8923826.
6. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995, 87(3):190-197. 10.1093/jnci/87.3.190, 7707406.
7. Paridaens R, Thomas J, Wildiers J, Vermeiren P, Lobelle JP, di Salle E, Ornati G, Zurlo MG, Polli A, Lanzalone S, et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study. Anticancer Drugs 1998, 9(8):675-683. 10.1097/00001813-199809000-00002, 9823425.
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group (EBCTCG)..
9. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348(24):2431-2442. 10.1056/NEJMra023246, 12802030.
10. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20(3):751-757. 10.1200/JCO.20.3.751, 11821457.
11. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007, 110(2):244-254. 10.1002/cncr.22789, 17538978.
12. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001, 12(11):1527-1532. 10.1023/A:1013128213451, 11822750.
13. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19(18):3808-3816.
14. Smith I, Dowsett M, . trialists oboI Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in posmenopausal women: The IMPACT trial. Breast Cancer Res Treat 2003, 82(suppl 2):S9-S15. trialists oboI.
15. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004, 96(12):936-945.
16. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13(1):94-101. 10.1158/1055-9965.EPI-03-0026, 14744739.
17. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007, 67(5):1893-1897. 10.1158/0008-5472.CAN-06-4123, 17325027.
18. Ribeiro FS, de Amorim LM, de Almeida Simao T, Mendonca GA, de Moura Gallo CV, Pinto LF. CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women. Toxicol Lett 2006, 164(1):90-95. 10.1016/j.toxlet.2005.11.014, 16406421.
19. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998, 8(1):43-48. 10.1097/00008571-199802000-00006, 9511180.
20. Baxter SW, Choong DY, Eccles DM, Campbell IG. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001, 22(2):347-349. 10.1093/carcin/22.2.347, 11181459.
21. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, Henderson BE. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999, 6(2):165-173. 10.1677/erc.0.0060165, 10731105.
22. Thyagarajan B, Brott M, Mink P, Folsom AR, Anderson KE, Oetting WS, Gross M. CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Cancer Lett 2004, 207(2):183-189. 10.1016/j.canlet.2003.12.009, 15072827.
23. Ralph DA, Zhao LP, Aston CE, Manjeshwar S, Pugh TW, DeFreese DC, Gramling BA, Shimasaki CD, Jupe ER. Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer 2007, 109(10):1940-1948. 10.1002/cncr.22634, 17436274.
24. Olson JE, Ingle JN, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Wu Y, Couch FJ, et al. A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 2007, 102(2):237-247. 10.1007/s10549-006-9324-7, 17004113.
25. Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Karesen R, Kristensen T, Borresen-Dale AL. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000, 19(10):1329-1333. 10.1038/sj.onc.1203425, 10713674.
26. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11(2):215-216.
27. Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, Geiler S, Ringleff K, Oeser S, Weihbrecht S, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 2008, 112(1):89-98. 10.1007/s10549-007-9822-2, 18049890.
28. Long JR, Kataoka N, Shu XO, Wen W, Gao YT, Cai Q, Zheng W. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 2006, 15(11):2115-2122. 10.1158/1055-9965.EPI-06-0464, 17119036.
29. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Munoz M, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008, 14(3):811-816. 10.1158/1078-0432.CCR-07-1923, 18245543.
30. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41(3A):151. Comment on C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403-410, 10.1046/j.1365-2559.2002.14691.x, 12405945.
31. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001, 19(6):1698-1706.
32. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005, 65(23):11071-11082. 10.1158/0008-5472.CAN-05-1218, 16322257.
33. Stern C. The Hardy-Weinberg Law. Science 1943, 97(2510):137-138. 10.1126/science.97.2510.137, 17788516.
34. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
35. Peto R, Peto P. Asymptomatically efficient rank invariant test procedures. J Roy Stat Soc 1987, 135:185-206.
36. Cox D. Regression models and life tables. J R Stat Soc 1972, 34:187-220.
37. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47(1):207-214. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6, 7459811.
38. Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005, 95(1-5):167-172. 10.1016/j.jsbmb.2005.04.022, 15982868.
39. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008, 100(9):642-648. 10.1093/jnci/djn100, 18445827.
40. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B, Sebastian S. Organization of the human aromatase p450 (CYP19) gene. Seminars in reproductive medicine 2004, 22(1):5-9. 10.1055/s-2004-823022, 15083376.
41. Rhiem K, Klein A, Munch M, Kreutzfeld R, Ramser J, Wardelmann E, Schackert G, Von Deimling A, Wiestler OD, Schmutzler RK. Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. Int J Cancer 2003, 106(1):74-77. 10.1002/ijc.11169, 12794759.
42. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J Clin Oncol 2005, 23(11):2477-2492. 10.1200/JCO.2005.07.559, 15767642.
43. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007, 9(3):R37. 10.1186/bcr1732, 1929101, 17555561.